In the first Parallax episode of 2021, Ankur welcomed back Sukh Nijjer from Imperial College London to review the most impactful events and advances in cardiology from 2020.
In the first part of the episode, Ankur and Sukh focus on the mechanism of the coronavirus and its effects on the heart including clotting abnormality and troponin elevation. They discuss their clinical experiences and observations within the UK and US settings in light of the latest data. Sukh offers practical tips on how to approach patient management during this pandemic.
Following this, Ankur and Sukh analyse the controversial STRENGHT study in light of the results from REDUCE-IT. They discuss the different attitudes toward early cryoablation therapy in the context of STOP AF and EARLY-AF studies. Sukh reviews the findings of the RHAPSODY Phase 3 trial and the revolution of SGLT2 inhibitors in the treatment of heart failure.
Which COVID19 patients require risk stratification with a stress test? What are the take-home messages for physicians taking care of patients diagnosed with COVID19? What were the key trials of 2020? What can we learn from the negative results of the STRENGHT study? How have studies like STOP-AF influenced clinical practice?
Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.
Brought to you by Edwards: www.edwardstavr.com
In this week’s episode Ankur’s guest is Dr Mandeep R Mehra, Medical Director of Brigham Heart and Vascular Center and Professor of Medicine at Harvard Medical School.
Dr. Ankur Kalra invites Dr Salim S Virani to help simplify the concept of Lp(a) with answering key questions about its measurement and its place in practice and prevention.
Dr Khan talks about education in the US and his decision to move back to Pakistan. Ankur asks Sohail about his new professional home: NICVD, a free clinic providing primary heartcare for Pakistanis. They discuss some of the innovations Dr Khan works on to improve patient care that utilise simple but effective interventions. We learn more about free screening clinics and about Dr Khan’s work on the largest ever study in Pakistan on association of Lpa and CV disease in South Asians.
They talk about AI assisted consultation, learning pathways incorporating simulators for early career practitioners and the Flying Eye Hospital. Dr Cherwek shares his experiences about working with local teams globally and the work that goes into setting up trials across the world.
They discuss the importance of preventative medicine, their experience of reducing hypertension with non-pharmaceutical and pharmaceutical methods, and the significance of the integrated “team approach” when treating comorbid conditions such as hypertension. Athena also shares her thoughts on cardiologists’ responsibility to shape their patients’ lifestyle choices.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.
Chest pain is one of the most common reasons for an emergency room visit in the US, with almost 6 million ER visits annually, yet there is no consensus on how to compare the results from various hscTn assays. Tune in to hear Santiago outline the advantages and limitations of using hscTn as a standard biomarket to evaluate patients with suspected ACS in the ER.
Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.